Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients

Mark van den Boogaard, Matthijs Kox, Kieran L Quinn, Theo van Achterberg, Johannes G van der Hoeven, Lisette Schoonhoven, Peter Pickkers, Mark van den Boogaard, Matthijs Kox, Kieran L Quinn, Theo van Achterberg, Johannes G van der Hoeven, Lisette Schoonhoven, Peter Pickkers

Abstract

Introduction: Delirium occurs frequently in critically ill patients and is associated with disease severity and infection. Although several pathways for delirium have been described, biomarkers associated with delirium in intensive care unit (ICU) patients is not well studied. We examined plasma biomarkers in delirious and nondelirious patients and the role of these biomarkers on long-term cognitive function.

Methods: In an exploratory observational study, we included 100 ICU patients with or without delirium and with ("inflamed") and without ("noninflamed") infection/systemic inflammatory response syndrome (SIRS). Delirium was diagnosed by using the confusion-assessment method-ICU (CAM-ICU). Within 24 hours after the onset of delirium, blood was obtained for biomarker analysis. No differences in patient characteristics were found between delirious and nondelirious patients. To determine associations between biomarkers and delirium, univariate and multivariate logistic regression analyses were performed. Eighteen months after ICU discharge, a cognitive-failure questionnaire was distributed to the ICU survivors.

Results: In total, 50 delirious and 50 nondelirious patients were included. We found that IL-8, MCP-1, procalcitonin (PCT), cortisol, and S100-β were significantly associated with delirium in inflamed patients (n = 46). In the noninflamed group of patients (n = 54), IL-8, IL-1ra, IL-10 ratio Aβ1-42/40, and ratio AβN-42/40 were significantly associated with delirium. In multivariate regression analysis, IL-8 was independently associated (odds ratio, 9.0; 95% confidence interval (CI), 1.8 to 44.0) with delirium in inflamed patients and IL-10 (OR 2.6; 95% CI 1.1 to 5.9), and Aβ1-42/40 (OR, 0.03; 95% CI, 0.002 to 0.50) with delirium in noninflamed patients. Furthermore, levels of several amyloid-β forms, but not human Tau or S100-β, were significantly correlated with self-reported cognitive impairment 18 months after ICU discharge, whereas inflammatory markers were not correlated to impaired long-term cognitive function.

Conclusions: In inflamed patients, the proinflammatory cytokine IL-8 was associated with delirium, whereas in noninflamed patients, antiinflammatory cytokine IL-10 and Aβ1-42/40 were associated with delirium. This suggests that the underlying mechanism governing the development of delirium in inflamed patients differs from that in noninflamed patients. Finally, elevated levels of amyloid-β correlated with long-term subjective cognitive-impairment delirium may represent the first sign of a (subclinical) dementia process. Future studies must confirm these results.The study was registered in the Clinical Trial Register (NCT00604773).

References

    1. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001;27:1892–900. doi: 10.1007/s00134-001-1132-2.
    1. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus R. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;292:168–9.
    1. Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL, Shintani AK, Gordon SM, Canonico AE, Dittus RS, Bernard GR, Ely EW. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010;38:1513–20. doi: 10.1097/CCM.0b013e3181e47be1.
    1. van den Boogaard M, Schoonhoven L, Evers AW, van der Hoeven JG, van AT, Pickkers P. Delirium in critically ill patients: impact on long-term health-related quality of life and cognitive functioning. Crit Care Med. 2012;40:112–8. doi: 10.1097/CCM.0b013e31822e9fc9.
    1. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci. 1999;54:B239–46. doi: 10.1093/gerona/54.6.B239.
    1. Maclullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res. 2008;65:229–38. doi: 10.1016/j.jpsychores.2008.05.019.
    1. Marcantonio ER, Rudolph JL, Culley D, Crosby G, Alsop D, Inouye SK. Serum biomarkers for delirium. J Gerontol A Biol Sci Med Sci. 2006;61:1281–6. doi: 10.1093/gerona/61.12.1281.
    1. de Rooij SE, Van Munster BC, Korevaar J, Levi M. Cytokines and acute phase response in delirium. J Psychosom Res. 2007;62:521–5. doi: 10.1016/j.jpsychores.2006.11.013.
    1. van Munster BC, Bisschop PH, Zwinderman AH, Korevaar JC, Endert E, Wiersinga WJ, Oosten HE, Goslings JC, de Rooij SE. Cortisol, interleukins and S100B in delirium in the elderly. Brain Cogn. 2010. in press .
    1. Van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, de Rooij SE. Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc. 2008;56:1704–9. doi: 10.1111/j.1532-5415.2008.01851.x.
    1. Van Munster BC, Korevaar JC, Korse CM, Bonfrer JM, Zwinderman AH, de Rooij SE. Serum S100B in elderly patients with and without delirium. Int J Geriatr Psychiatry. 2009;25:234–9.
    1. Iacobone E, Bailly-Salin J, Polito A, Friedman D, Stevens RD, Sharshar T. Sepsis-associated encephalopathy and its differential diagnosis. Crit Care Med. 2009;37:S331–6.
    1. Pfister D, Siegemund M, ll-Kuster S, Smielewski P, Ruegg S, Strebel SP, Marsch SC, Pargger H, Steiner LA. Cerebral perfusion in sepsis-associated delirium. Crit Care. 2008;12:R63. doi: 10.1186/cc6891.
    1. Gunther ML, Jackson JC, Wesley EE. Loss of IQ in the ICU brain injury without the insult. Med Hypotheses. 2007;69:1179–82. doi: 10.1016/j.mehy.2007.03.039.
    1. Alexander JJ, Jacob A, Cunningham P, Hensley L, Quigg RJ. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int. 2008;52:447–56. doi: 10.1016/j.neuint.2007.08.006.
    1. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA. 2010;304:443–51. doi: 10.1001/jama.2010.1013.
    1. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:904–5. doi: 10.1016/j.neurobiolaging.2006.03.004.
    1. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655–60. doi: 10.1016/S1474-4422(06)70501-4.
    1. Lesur O, Roussy JF, Chagnon F, Gallo-Payet N, Dumaine R, Sarret P, Chraibi A, Chouinard L, Hogue B. Proven infection-related sepsis induces a differential stress response early after ICU admission. Crit Care. 2010;14:R131. doi: 10.1186/cc9102.
    1. Brenner T, Hofer S, Rosenhagen C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Lukic IK, Martin E, Bierhaus A, Hoffmann U, Weigand MA. Macrophage migration inhibitory factor (MIF) and manganese superoxide dismutase (MnSOD) as early predictors for survival in patients with severe sepsis or septic shock. J Surg Res. 2010;164:e163–71. doi: 10.1016/j.jss.2010.05.004.
    1. Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2008;295:H1817–24. doi: 10.1152/ajpheart.00472.2008.
    1. Aldemir M, Ozen S, Kara IH, Sir A, Bac B. Predisposing factors for delirium in the surgical intensive care unit. Crit Care. 2001;5:265–70. doi: 10.1186/cc1044.
    1. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, Hart RP, Dittus R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU) JAMA. 2001;286:2703–10. doi: 10.1001/jama.286.21.2703.
    1. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T, Gautam S, Bernard GR, Inouye SK. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) Crit Care Med. 2001;29:1370–9. doi: 10.1097/00003246-200107000-00012.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74. doi: 10.1097/00003246-199206000-00025.
    1. van den Boogaard M, Pickkers P, van der Hoeven H, Roodbol G, van Achterberg T, Schoonhoven L. Implementation of a delirium assessment tool in the ICU can influence haloperidol use. Crit Care. 2009;13:R131. doi: 10.1186/cc7991.
    1. Lachno DR, Vanderstichele H, De GG, Kostanjevecki V, De MG, Siemers ER, Willey MB, Bourdage JS, Konrad RJ, Dean RA. The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay. J Nutr Health Aging. 2009;13:220–5. doi: 10.1007/s12603-009-0062-5.
    1. Merckelbach H, Muris P, Nijman H, de Jong PJ. Self-reported cognitive failures and neurotic symptomatology. Personal Individ Differ. 1996;20:715–24. doi: 10.1016/0191-8869(96)00024-4.
    1. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(Pt 1):1–16.
    1. Wallace JC, Kass SJ, Stanny CJ. The Cognitive Failures Questionnaire revisited: dimensions and correlates. J Gen Psychol. 2002;129:238–56. doi: 10.1080/00221300209602098.
    1. van den Boogaard M, Schoonhoven L, Evers AW, van der Hoeven JG, van AT, Pickkers P. Delirium in critically ill patients: impact on long-term health-related quality of life and cognitive functioning. Crit Care Med. 2012;40:112–8. doi: 10.1097/CCM.0b013e31822e9fc9.
    1. Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis. 2010;21:291–301.
    1. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1:371–80. doi: 10.1002/emmm.200900048.
    1. Takeda S, Sato N, Rakugi H, Morishita R. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol Biosyst. 2010;6:1760–6. doi: 10.1039/c003148h.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 4. Washington, DC: American Psychiatric Association; 1994.
    1. Devlin JW, Fong JJ, Fraser GL, Riker RR. Delirium assessment in the critically ill. Intensive Care Med. 2007;33:929–40. doi: 10.1007/s00134-007-0603-5.
    1. van den Boogaard M, Pickkers P, Schoonhoven L. Assessment of delirium in ICU patients; a literature review. Netherlands J Crit Care. 2010;14:10–15.
    1. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705–10.
    1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44. doi: 10.1038/nrneurol.2010.4.
    1. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354–62. doi: 10.1001/archneur.64.3.354.
    1. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46:412–6. doi: 10.1002/1531-8249(199909)46:3<412::AID-ANA19>;2-A.
    1. Pomara N, Shao B, Wisniewski T, Mehta PD. Decreases in plasma A beta 1-40 levels with aging in non-demented elderly with ApoE-epsilon 4 allele. Neurochem Res. 1998;23:1563–6. doi: 10.1023/A:1020936222286.
    1. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry. 2005;13:914–7.
    1. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25:273–81. doi: 10.1016/S0197-4580(03)00086-1.
    1. Zimmermann R, Kornhuber J, Lewczuk P. [The future of biomarkers in dementia diagnostics.] Nervenarzt. 2011;82:1385–86. doi: 10.1007/s00115-011-3348-x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe